

Andres Pineda, Fscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7122227/publications.pdf>

Version: 2024-02-01

17
papers

322
citations

1163117

8
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

526
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 452-461.	3.0	2
2	Identifying opportunities to advance health equity in interventional cardiology: Structural heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1165-1171.	1.7	1
3	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351.	3.4	5
4	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737.	3.0	6
5	Type A Aortic Dissection Following a Transcatheter Aortic Valve Replacement in a Prohibitive Surgical Risk Candidate. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	1.3	1
6	Racial and ethnic disparities in coronary, vascular, structural, and congenital heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 277-294.	1.7	18
7	Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
8	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502.	1.6	10
9	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428.	4.1	18
10	Trends in Usage and Clinical Outcomes of Coronary Atherectomy. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008239.	3.9	36
11	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008227.	3.9	49
12	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549.	2.9	26
13	Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1577-1579.	2.9	2
14	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670.	1.6	106
15	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	4.1	12
16	Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 740-748.	1.7	27
17	Challenges for Expanded Use of Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	3